Antiangiogenic and cytotoxic activity of boswellic acid on breast cancer MCF-7 cells

Biomedicine and Preventive Nutrition

Volumn 2, Issue 1, 2012, Pages 31-37

  Saraswati, Sarita ^a   Agrawal, S S ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Angiogenesis; Apoptosis; Boswellic acid MCF 7; Vascular endothelial growth factor

Indexed keywords

BOSWELLIC ACID; CASPASE 3; CASPASE 9; CHLORAMPHENICOL ACETYLTRANSFERASE; INTERLEUKIN 12; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTICENTER STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

EID: 84858297908     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2011.09.006     Document Type: Article

References (45)

1. Pisani P. Breast cancer: geographic variation and risk factors. J Environ Pathol Toxicol Oncol 1992, 11:313-316.
2. Saxena S., Rekhi B., Bansal A., Bagga A., Murthy N.S. Clinicomorphological patterns of breast cancer including family history in a New Delhi hospital Indian - A cross-sectional study. World J Surg Oncol 2005, 3:67-72.
3. Bagchi S. Breast cancer rise in India. CMAJ 2008, 179:27.
4. Folkman J. Tumor angiogenesis: therapeutic implications. NEJM 1971, 285:1182-1186.
5. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5:37-44.
6. Gerwins P., Skoldenberg E., Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2004, 34:185-194.
7. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cyto Growth Factor Rev 1997, 8:21-43.
8. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Hoeben A., Landuyt B., Highley M.S., Wildiers H., van Oosterom A.T., Bruijin EAD Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 6:549-580.
11. Millauer B., Longhi M.P., Plate K.H., Shawyer K., Atrwan L.M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56:1615-1620.
12. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
13. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Wang W., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
14. Dhanabal M., Jeffers M., Larochelle W.J. Antiangiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 2005, 5:115-130.
15. De Smet F., Carmeliet P., Autiero M. Fishing and frogging for antiangiogenic drugs. Nat Chem Biol 2006, 2:228-229.
16. Sharma M.L.S., Bani S., Singh G.B. Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int J Immunopharmacol 1989, 11:647-652.
17. Safayhi H., Mack T., Ammon H.P. Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1991, 41:1536-1537.
18. Gupta I., Parihar A., Malhotra P., Singh G.B., Ludtke R., Safayhi H., Ammon H.P. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997, 2:37-43.
19. Gupta I., Gupta V., Parihar A., Gupta S., Ludtke R., Safayhi H., Ammon H.P. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a doubleblind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998, 3:511-514.
20. Gupta I., Parihar A., Malhotra P., Gupta S., Ludtke R., Safayhi H., Ammon H.P. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001, 67:391-395.
21. Gerhardt H., Seifert F., Buvari P., Vogelsang H., Repges R.Z. Therapie desaktiven Morbus Crohn mit Boswellia serrata extract H 15 Z. Gastroenterology 2001, 39:11-17.
22. Singh G.B., Atal C.K. Pharmacology of an extract of salai guggal ex Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986, 18:407-412.
23. Sharma M.L., Kaul A., Khajuria A., Singh S., Singh G.B. Immunomodulatory activity of boswellic acids (pentacyclic triterpene acids) from Boswellia serrata. Phytother Res 1996, 10:107-112.
24. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12:53-63.
25. Ammon H.P., Safayhi H., Mack T., Sabieraj J. Mechanism of anti-inflammatory actions of curcumin and boswellic acids. J Ethnopharmacol 1993, 38:113-119.
26. Safayhi H., Mack T., Sabieraj J., Anazodo M.I., Subramanian L.R., Ammon H.P. Boswellic acids: novel, specific, non redox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992, 261:1143-1146.
27. Sailer E.R., Subramanian L.R., Rall B., Hoernlein R.F., Ammon H.P., Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996, 117:615-618.
28. Safayhi H., Sailer E.R., Ammon H.P. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995, 47:1212-1216.
29. Glaser T., Winter S., Groscurth P., Safayhi H., Sailer E.R., Ammon H.P., Schabet M., Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999, 80:756-765.
30. Zhao W., Entschladen F., Liu H., Niggemann B., Fang Q., Zaenker K.S., Han R. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detec Prev 2003, 27:67-75.
31. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Antitumor properties of Boswellic acid against Ehrlich ascites cells bearing mouse. Food Chem Toxicol 2011, 49:1924-1934.
32. Singh S.K., Bhusari S., Singh R., Saxena A., Mondhe D., Qazi G.N. Effect of acetyl 11-keto β-boswellic acid on metastatic growth factor responsible for angiogenesis. Vasc Pharmacol 2007, 46:333-337.
33. Winking M., Sarikaya S., Rahmanian A., Jodicke A., Boker D.K. Boswellic acids inhibit glioma growth: a new treatment option?. J Neurooncol 2000, 46:97-103.
34. Shao Y., Ho C.T., Chin C.K., Badmaev V., Ma W., Huang M.T. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med 1998, 64:328-331.
35. Hoernlein R.F., Orlikowsky T., Zehrer C., Niethammer D., Sailer E.R., Simmet T., Dannecker G.E., Ammon H.P. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther 1999, 288:613-619.
36. Jing Y., Nakajo S., Xia L., Nakaya K., Fang Q., Waxman S., Han R. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res 1999, 23:43-50.
37. Syrovets T., Buchele B., Krauss C., Laumonnier Y., Simmet T. Acetyl boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinase. J Immunol 2005, 174:498-506.
38. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Cytotoxic and antitumor effects of brucine on Ehrlich ascites tumor and human cancer cell line. Life Sci 2011, 89:147-158.
39. Bradford M.M. A dye binding assay for protein. Anal Biochem 1976, 72:248-254.
40. Fargeot P., Bonneterre J., Roche H., Lortholary A., Campone M., Praagh I.V., Monnier A., Namer M., Schraub S., Barats J.C., Guastalla J.P., Goudier M.J., Chapelle-Marcillac I. Disease-free survival advantage of weekly Epirubicin plus Tamoxifen versus Tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trials. J Clin Oncol 2004, 22:4622-4630.
41. Hebert-Croteau N., Brisson J., Latreille J., Rivard M., Abdelaziz N., Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004, 22:3685-3693.
42. Fitzgerald J.B., Schoeberl B., Nielsen U.B., Sorger P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006, 2:458-466.
43. Ghosh S., Maity P. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth. Int Immunopharmacol 2006, 6:1550-1559.
44. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 1998, 95:13182-13187.
45. Avis I., Hong S.H., Martinez A., Moody T., Choi Y.H., Trepel J., Das R., Jett M., Mulshine J.L. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001, 15:2007-2009.